Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
The present application relates to a hydrogen peroxide-responsive Keap1-Nrf2 PPI inhibitor prodrug, and a preparation method therefor. The hydrogen peroxide-responsive Keap1-Nrf2 PPI inhibitor prodrug pro2 has a chemical structure as shown below. By modifying a key carboxyl pharmacophore in a Keap1-Nrf2 inhibitor with a H 2 O 2 -responsive thiazolidinone moiety, a novel ROS-responsive antioxidant prodrug pro2 is synthesized. The H 2 O 2 activated prodrug pro2 can simultaneously achieve targeted activation of Nrf2 and enhancement of therapeutic efficacy in the body. The prodrug is based on the concept of ROS activation-ROS clearance therapy, is the first example of a H 2 O 2 -responsive prodrug suitable for oral administration, and is expected to be used clinically by virtue of the characteristics of druggability and high targeting ability.
1. A prodrug pro2 of hydrogen peroxide-responsive Keap1-Nrf2 PPI inhibitor having the following structural formula:
2. A method for preparing a prodrug pro2, wherein a synthetic route is as follows:
wherein, the reagents and conditions in each step are as follows:
(b) Pd/C, H 2 , THF, rt, 4 h;
(c) 4-methoxybenzenesulfonyl chloride, Na 2 CO 3 , THF, 0° C., 2 h;
(d) 4-methoxybenzenesulfonyl chloride, toluene, pyridine, 100° C., 2 h;
(e) DMF, K 2 CO 3 , ethyl bromoacetate, rt, 3 h;
(f) LiOH, MeOH, H 2 O, 2 h; and
(g) thiazolidin-2-one, DMAP, DCC, DMF, rt, 6 h.
3. The method according to claim 2 , wherein compound 4 is synthesized by the following route:
wherein, the reagents and conditions in the step (a) are as follows: NH 2 OH·HCl, 95% ethanol, MeOH, 60° C., and 2 h.
4. A method for preparing a prodrug pro2 in preparing an anti-inflammatory drug, the prodrug pro2 having the following structural formula:
5. The method according to claim 4 , wherein the drug increases levels of Nrf2 and downstream antioxidant enzymes, and enhances the activation of the Nrf2-ARE system at a cellular level.
6. The method according to claim 4 , wherein the drug inhibits expression of pro-inflammatory factors IL-1β and IL-6 at a protein level.
7. The method according to claim 4 , wherein the drug is for oral administration.